Sagimet down as Chinese partner posts late-stage trial data for acne therapy
Source: SeekingAlpha
2026-01-29 08:17:13 ET
More on Sagimet Biosciences, Ascletis Pharma Inc.
- Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market
- Sagimet Biosciences Advances Denifanstat: Q3 Earnings And Upcoming Catalysts
- Sagimet rises as licensing deal with Teva unit targets Madrigal drug
- Seeking Alpha’s Quant Rating on Sagimet Biosciences
- Historical earnings data for Sagimet Biosciences
Read the full article on Seeking Alpha
For further details see:
Sagimet down as Chinese partner posts late-stage trial data for acne therapy
Ascletis Pharma Inc.
NASDAQ: ASCLF
ASCLF Trading
0.0% G/L:
$1.955 Last:
447 Volume:
$1.955 Open:
